RTTNews | Sep 29, 2021 07:21AM EDT

07:21 Wednesday, September 29, 2021 (RTTNews.com) - NRx Pharmaceuticals (NRXP) said the Independent Data Safety Monitoring Board found no new safety concerns in the ACTIV-3b Critical Care phase 3 study, after reviewing 231 patients, and recommended continued enrollment. ACTIV-3b is a randomized, placebo-controlled trial testing ZYESAMI and remdesivir - alone and in combination - in hospitalized patients with acute respiratory failure due to COVID-19 who require high-flow supplemental oxygen.

"With this second independent safety analysis in the ACTIV-3b trial, the safety database on ZYESAMI has grown to more than 500 patients. So far, there have been no reports of unexpected, drug-related serious adverse events," said Jonathan Javitt, CEO of NRx.

Read the original article on RTTNews ( https://www.rttnews.com/3229033/nrx-pharma-data-safety-monitoring-board-finds-no-new-safety-concerns-in-activ-3b-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved